Travis A, Pinder S E, Robertson J F, Bell J A, Wencyk P, Gullick W J, Nicholson R I, Poller D N, Blamey R W, Elston C W, Ellis I O
Department of Histopathology, City Hospital, Nottingham, UK.
Br J Cancer. 1996 Jul;74(2):229-33. doi: 10.1038/bjc.1996.342.
A series of 346 patients with primary operable breast cancer and a series of 145 patients with advanced breast cancer were investigated for c-erbB-3 protein expression using the monoclonal antibody RTJ1. Formalin-fixed, paraffin-embedded tumour samples were stained using a standard immunochemical method and staining was assessed on a four-point scale. The study aimed to observe the expression of the c-erbB-3 protein and investigate any relationship between expression and established prognostic indicators and prognosis. In both the primary and advanced series breast tumour tissue was found to stain heterogeneously for c-erbB-3. The staining was observed to be predominantly cytoplasmic and the majority of tumours exhibited moderate positivity. However, 15% and 35% of cases in the primary operable and advanced series respectively displayed strong positive staining. No significant difference was found between the staining in the primary and advanced series. In the primary operable breast cancers, no significant associations were demonstrated with overall survival, disease-free interval, regional recurrence, the presence of distant metastases, age, menopausal status, oestrogen receptor status, histological grade, lymph node stage, vascular invasion and c-erbB-2 protein expression. However, a significant association was seen between the degree of c-erbB-3 immunoreactivity and both tumour size (P < 0.01) and tumour type prognostic group (P = 0.05). No overall association with local recurrence was seen when the four groups of c-erbB-3 expression were analysed (P = 0.12), but when those tumours showing no or weak staining were compared with those showing moderate and strong immunoreactivity it was seen that the latter were significantly more likely to develop local recurrence (P = 0.03). In the series of patients with advanced disease, no significant associations were demonstrated with survival, UICC criteria, age, menopausal status, oestrogen receptor status, histological grade, c-erbB-2 status or the presence of vascular invasion. In conclusion this study found variable expression of c-erbB-3 protein in human breast carcinoma and an association with some recognised prognostic factors in those patients with primary operable breast carcinoma. It seems, however, unlikely that c-erbB-3 protein expression will emerge as a powerful enough prognostic factor to be of value in clinical practice.
使用单克隆抗体RTJ1对346例原发性可手术乳腺癌患者和145例晚期乳腺癌患者进行了c-erbB-3蛋白表达情况的研究。采用标准免疫化学方法对福尔马林固定、石蜡包埋的肿瘤样本进行染色,并按四分制评估染色情况。该研究旨在观察c-erbB-3蛋白的表达,并探究其表达与既定预后指标及预后之间的关系。在原发性和晚期系列中,均发现乳腺肿瘤组织对c-erbB-3的染色呈异质性。观察到染色主要位于细胞质,且大多数肿瘤表现为中度阳性。然而,原发性可手术系列和晚期系列中分别有15%和35%的病例显示强阳性染色。原发性和晚期系列的染色之间未发现显著差异。在原发性可手术乳腺癌中,未发现其与总生存期、无病间期、区域复发、远处转移的存在、年龄、绝经状态、雌激素受体状态、组织学分级、淋巴结分期、血管侵犯及c-erbB-2蛋白表达之间存在显著关联。然而,c-erbB-3免疫反应程度与肿瘤大小(P < 0.01)及肿瘤类型预后分组(P = 0.05)之间均存在显著关联。对c-erbB-3表达的四组进行分析时,未发现其与局部复发存在总体关联(P = 0.12),但当将无染色或弱染色的肿瘤与中度和强免疫反应性的肿瘤进行比较时,发现后者发生局部复发的可能性显著更高(P = 0.03)。在晚期疾病患者系列中,未发现其与生存期、国际抗癌联盟(UICC)标准、年龄、绝经状态、雌激素受体状态、组织学分级、c-erbB-2状态或血管侵犯的存在之间存在显著关联。总之,本研究发现人乳腺癌中c-erbB-3蛋白表达存在差异,且在原发性可手术乳腺癌患者中其与一些公认的预后因素相关。然而,c-erbB-3蛋白表达似乎不太可能成为强大到足以在临床实践中具有价值的预后因素。